Abstract |
In this open phase-II clinical tolerability trial 17 neurologists enrolled a total of 112 patients and instructed them to administer a maximum of two doses of intranasal alniditan, a 5-HT1B/D receptor agonist, for the treatment of three consecutive migraine attacks of moderate to severe intensity. A second dose of the trial medication was allowed within 1-24 h after the first administration. At 1 h after intranasal administration, 70/103 (68%) patients had responded to treatment (reduction from severe or moderate headache before treatment to mild or no headache) after their first migraine attack, 65/94 (69%) after their second and 52/75 (71%) after their third. In 187/270 (69%) of all attacks, patients were considered responders at 1 h. The median time to onset of effect was 30 min. The migraine headache recurred in 44% (attack 1), 55% (attack 2) and 44% (attack 3) after 4-5 h. Sixty-eight per cent of the patients reported nasal irritation, 19% taste disturbance and 44% throat irritation. Alniditan 2 mg, administered via the intranasal route, was effective in relieving migraine headaches in over two-thirds of the patients at 1 h.
|
Authors | H C Diener, P Louis, R Schellens, F De Beukelaar, Study Group |
Journal | Cephalalgia : an international journal of headache
(Cephalalgia)
Vol. 21
Issue 2
Pg. 140-4
(Mar 2001)
ISSN: 0333-1024 [Print] England |
PMID | 11422097
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Benzopyrans
- Propylamines
- Pyrimidines
- Vasoconstrictor Agents
- alniditan
|
Topics |
- Administration, Intranasal
- Adolescent
- Adult
- Aged
- Benzopyrans
(administration & dosage, adverse effects)
- Dose-Response Relationship, Drug
- Female
- Humans
- Male
- Middle Aged
- Migraine Disorders
(drug therapy)
- Propylamines
(administration & dosage, adverse effects)
- Pyrimidines
(administration & dosage, adverse effects)
- Treatment Outcome
- Vasoconstrictor Agents
(administration & dosage, adverse effects)
|